Training program in cancer pharmacology

癌症药理学培训计划

• 批准号: 8535614
• 负责人: Ian Alexander Blair
• 金额: $ 50.49万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-24 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8535614
• 关键词: Area; B-Lymphocytes; Back; Biological Markers; Biological Models; Cancer Etiology; Cancer Patient; Cells; Clinical; Clinical Pharmacology; Clinical Research; Clinical Trials; Clinical and Translational Science Awards; Communities; Development; Discipline; Doctor of Philosophy; Dose; Education; Educational Curriculum; Environment; Epidemiology; Faculty; Funding; Funding Opportunities; Goals; Grant; Hematology; Human; Individual; Institutes; Institution; Institutional National Research Service Award; Interdisciplinary Study; Laboratories; Lead; Leadership; Learning; Malignant Neoplasms; Master' s Degree; Measures; Medicine; Mentors; Methodology; Molecular; Pediatric Hospitals; Pennsylvania; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacogenetics; Phase I Clinical Trials; Philadelphia; Play; Postdoctoral Fellow; Process; Qualifying; Research; Research Personnel; Research Training; Resources; Role; Scientist; Signal Transduction; Students; Testing; Therapeutic; Therapeutic Agents; Time; Training; Training Program for Cancer Prevention and Control Scientists (R25); Training Programs; Training and Education; Translational Research; Translations; Universities; Update; Validation; Work; anticancer research; base; cancer cell; cancer pharmacology; career; career development; chemotherapeutic agent; design; experience; frontier; interdisciplinary approach; meetings; multidisciplinary; next generation; novel therapeutics; oncology; patient population; pre-doctoral; programs; small molecule; translational medicine

DESCRIPTION (provided by applicant): The purpose of the interdisciplinary Cancer Pharmacology training program is to continue providing seven predoctoral students and three postdoctoral fellows with a training environment that did not exist at the University of Pennsylvania prior to the development of the present program. Drs. Blair (Program Director), Lee (Program Co-Director), and Penning (Program Co-Director) will provide the sustained leadership required to continue development of the Cancer Education and Career Development Program (CECDP). Major advances in the treatment of cancer patients in the next decade will result from multidisciplinary approaches in understanding of how malignant cells work at the molecular level and in designing novel therapeutic agents to disrupt these processes. Therefore, the CECDP will help fill the current deficit of individuals qualified to develop the next generation of chemotherapeutic agents. The ultimate goal of the program is to provide training in cancer pharmacology that goes from laboratory to bedside and back again. Specifically, trainees will learn how cancer pharmacology can be used to identify new targets, how small molecules are synthesized and tested against these targets, how they are used in Phase I trials, how these studies are developed into full clinical trials, and how epidemiology and pharmacogenetics can be utilized to assess efficacy and lead to the discovery of new targets. Trainees will also receive specific training in how to project quantitative measures of drug effect from proof of concept in model systems into the rational selection of dosing in humans. These goals will be accomplished through the courses and interdisciplinary research experience that are offered in the CECDP. There are thirty faculty mentors with diverse complementary expertise who belong to eight of the nine graduate groups that are involved in Biomedical Graduate Studies at the University of Pennsylvania. Mentors are grouped into three sub-programs within the CECDP: A. Cancer Etiology and Therapeutics. B. Cell and Molecular Cancer Pharmacology. C. Clinical Cancer Pharmacology. Each trainee will have two research mentors affiliated with two different sub-programs. The mentors have a very strong record of accomplishment as cancer researchers as well as superb access to different patient populations through their association with NCI-funded clinical programs. Furthermore, one of the mentors is Director of the Institute of Translation Medicine and the Clinical Translational Science Award at the University of Pennsylvania (Dr. Garret FitzGerald) and one is Division Chief, Clinical Pharmacology and Therapeutics, and Director of the Office of Clinical and Translational Research at the Children's Hospital of Philadelphia (Dr. Peter Adamson). Both of these mentors have research programs with a focus on translational therapeutics and so they provide another outstanding training resource. The Master's program in Translational Research (MTR) and new clinical leadership provided by Dr. Lee from the Division of Hematology/Oncology will provide additional translational opportunities. The MTR program will be available to trainees in addition to their conventional PhD and postdoctoral studies. Goals of the CECDP in Cancer Pharmacology will be accomplished through three specific aims. Specific Aim 1: To provide unique didactic experiences to trainees in the field of cancer pharmacology. Specific Aim 2: To provide interdisciplinary research training in cancer pharmacology to predoctoral students and postdoctoral fellows. Specific Aim 3: To provide predoctoral and postdoctoral researchers with training in translational medicine and cancer therapeutics.

描述（由申请人提供）：跨学科癌症药理学培训计划的目的是继续为七名博士前学生和三名博士后研究员提供在本计划开发之前不存在于宾夕法尼亚大学的培训环境。Blair博士（项目主任）、Lee博士（项目联合主任）和Penning博士（项目联合主任）将为癌症教育和职业发展项目（CECDP）的持续发展提供所需的持续领导。未来十年癌症患者治疗的重大进展将来自多学科方法，以了解恶性细胞如何在分子水平上工作，并设计新的治疗药物来破坏这些过程。因此，CECDP将有助于填补目前有资格开发下一代化疗药物的个人的不足。该计划的最终目标是提供从实验室到床边再回来的癌症药理学培训。具体而言，学员将学习如何使用癌症药理学来确定新的靶点，如何合成小分子并针对这些靶点进行测试，如何在I期试验中使用它们，如何将这些研究发展为完整的临床试验，以及如何利用流行病学和药物遗传学来评估疗效并发现新靶点。学员还将接受如何从模型系统的概念证明到人类剂量的合理选择中投射药物效果的定量测量的具体培训。这些目标将通过CECDP提供的课程和跨学科研究经验来实现。有30名教师导师具有不同的互补专业知识，他们属于参与宾夕法尼亚大学生物医学研究生研究的九个研究生小组中的八个。在CECDP中，导师分为三个子项目：癌症病因学和治疗学。B。细胞和分子癌症药理学。C.临床癌症药理学。每个学员将有两个研究导师隶属于两个不同的子程序。导师们作为癌症研究人员有着非常出色的成就记录，并且通过与NCI资助的临床项目的联系，能够接触到不同的患者群体。此外，其中一位导师是宾夕法尼亚大学翻译医学研究所所长和临床转化科学奖（Garret FitzGerald博士），另一位导师是临床药理学和治疗学部门主任兼临床和转化研究办公室主任费城儿童医院（Peter Adamson博士）。这两位导师都有专注于转化治疗学的研究项目，因此他们提供了另一种出色的培训资源。在转化研究（MTR）硕士课程和新的临床领导由李博士从血液学/肿瘤学的部门提供将提供额外的翻译机会。中期审查计划将提供给学员除了他们传统的博士和博士后研究。癌症药理学CECDP的目标将通过三个具体目标来实现。具体目标1：为癌症药理学领域的学员提供独特的教学经验。具体目标2：为博士前学生和博士后研究员提供癌症药理学的跨学科研究培训。具体目标3：为博士前和博士后研究人员提供转化医学和癌症治疗方面的培训。

项目成果

Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.

• DOI: 10.1371/journal.pone.0050099
• 发表时间: 2012
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Zhu J;Siclari VA;Liu F;Spatz JM;Chandra A;Divieti Pajevic P;Qin L
• 通讯作者: Qin L

Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.

• DOI: 10.1158/0008-5472.can-10-2286
• 发表时间: 2010-12-01
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Gilad O;Nabet BY;Ragland RL;Schoppy DW;Smith KD;Durham AC;Brown EJ
• 通讯作者: Brown EJ

Mesenchymal progenitors residing close to the bone surface are functionally distinct from those in the central bone marrow.

• DOI: 10.1016/j.bone.2012.12.013
• 发表时间: 2013-04
• 期刊: BONE
• 影响因子: 4.1
• 作者: Siclari, Valerie A.;Zhu, Ji;Akiyama, Kentaro;Liu, Fei;Zhang, Xianrong;Chandra, Abhishek;Nah, Hyun-Duck;Shi, Songtao;Qin, Ling
• 通讯作者: Qin, Ling

Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.

• DOI: 10.1038/onc.2012.240
• 发表时间: 2013-05-02
• 期刊: ONCOGENE
• 影响因子: 8
• 作者: Furcht, C. M.;Rojas, A. R. Munoz;Nihalani, D.;Lazzara, M. J.
• 通讯作者: Lazzara, M. J.

Nutrient-sensing pathways and metabolic regulation in stem cells.

• DOI: 10.1083/jcb.201303110
• 发表时间: 2013-10-14
• 期刊: The Journal of cell biology
• 作者: Ochocki JD;Simon MC
• 通讯作者: Simon MC